Lucas Mikulic, MD
Pulmonary Disease · Clearwater, FLNPI 1093998742
Payments from drug & device makers
Across 216 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$601
- GSK$510
- Insmed, Inc.$463
- Boehringer Ingelheim$257
- Actelion Pharmaceuticals US, Inc.$253
- Amgen$253
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,207100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 35 | $601 |
| GSK | 28 | $510 |
| Insmed, Inc. | 29 | $463 |
| Boehringer Ingelheim | 13 | $257 |
| Actelion Pharmaceuticals US, Inc. | 11 | $253 |
| Amgen | 14 | $253 |
| Regeneron Healthcare Solutions, Inc. | 11 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $197 |
| Merck | 7 | $179 |
| AbbVie(2 entities) | 7 | $161 |
| United Therapeutics Corporation | 5 | $127 |
| Bayer | 6 | $118 |
| Sanofi | 5 | $105 |
| Grifols USA, LLC | 4 | $87 |
| Inspire Medical Systems, Inc. | 2 | $77 |
| Mylan Specialty L.p. | 3 | $74 |
| Vapotherm Inc | 3 | $67 |
| Shionogi Inc | 3 | $66 |
| Electromed, Inc. | 4 | $56 |
| Johnson & Johnson | 1 | $43 |
| Pfizer | 3 | $38 |
| Circassia Inc. | 3 | $36 |
| Portola Pharmaceuticals, LLC | 2 | $33 |
| Novartis | 2 | $28 |
| Verona Pharma, Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Gilead | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| CSL Behring | 1 | $16 |
| Philips North America LLC | 1 | $13 |
| Inogen, Inc. | 1 | $4 |
How this compares
$4,207 in reported general payments places this provider in the 50th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 16 | $207,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 151 | $149,126 |
| NucalaMepolizumab | 14 | $59,950 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 49 | $38,221 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $31,068 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $26,434 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 51 | $23,145 |
| Spiriva RespimatTiotropium Bromide | 16 | $17,291 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $9,225 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 16 | $7,777 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,456 |
| Spiriva HandihalerTiotropium Bromide | 13 | $6,732 |
| XareltoRivaroxaban | 12 | $6,568 |
| EliquisApixaban | 11 | $6,285 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 113 | $3,446 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $510 | $263,289264 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $257 | $259,25280 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $601 | $45,67770 claims |
| Johnson & JohnsonXarelto | $43 | $6,56812 claims |
| PfizerEliquis | $38 | $6,28511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Clearwater
- Francis AverillClearwater$6.3M
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.